Depomed to Announce First Quarter 2008 Financial Results on May 1, 2008.

MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter financial results for 2008 after the market closes on Thursday, May 1, 2008. The company will webcast a conference call beginning at 4:30 p.m. ET, 1:30 p.m. PT to discuss its results and to provide an update and future outlook on company events.

Interested parties can access the live and archived broadcast of the call at www.depomedinc.com.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm(TM) drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA([R]) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes. ProQuin([R]) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate Gabapentin GR([R]) is currently in clinical development for the treatment of neuropathic pain and menopausal hot flashes. Additional information about Depomed may be found on its website, www.depomed.com.